(Q37738580)

22 August 2017

1 reference

title

Treatment of relapsed and refractory myeloma (English)

1 reference

22 August 2017

3

Sagar Lonial

1 reference

22 August 2017

Jonathan Kaufman

1

1 reference

22 August 2017

Charise Gleason

series ordinal

2

1 reference

22 August 2017

publication date

1 April 2009

1 reference

Current hematologic malignancy reports

22 August 2017

published in

1 reference

22 August 2017

volume

4

1 reference

22 August 2017

issue

2

1 reference

22 August 2017

page(s)

99-107

1 reference

Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma

22 August 2017

cites work

1 reference

12 December 2020

Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma

1 reference

12 December 2020

Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma

1 reference

12 December 2020

Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma.

1 reference

12 December 2020

The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma

1 reference

12 December 2020

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

1 reference

12 December 2020

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial

1 reference

12 December 2020

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression

1 reference

12 December 2020

Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure

1 reference

12 December 2020

Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications

1 reference

12 December 2020

Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma

1 reference

12 December 2020

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

1 reference

12 December 2020

Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells

1 reference

12 December 2020

1 reference

12 December 2020

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

1 reference

12 December 2020

Thalidomide for treatment of multiple myeloma: 10 years later

1 reference

12 December 2020

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

1 reference

12 December 2020

Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma

1 reference

12 December 2020

Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma

1 reference

12 December 2020

Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib

1 reference

12 December 2020

Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma

1 reference

12 December 2020

Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies

1 reference

12 December 2020

1 reference

12 December 2020

Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma

1 reference

12 December 2020

Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin

1 reference

12 December 2020

Solitary bone plasmacytoma: outcome and prognostic factors following radiotherapy

1 reference

12 December 2020

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

12 December 2020

Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials

1 reference

12 December 2020

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

1 reference

12 December 2020

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

1 reference

12 December 2020

Immunomodulatory analogs of thalidomide: an emerging new therapy in myeloma

1 reference

12 December 2020

Advances in biology of multiple myeloma: clinical applications

1 reference

12 December 2020

Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma

1 reference

12 December 2020

A phase 2 study of bortezomib in relapsed, refractory myeloma

1 reference

12 December 2020

Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma

1 reference

12 December 2020

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

1 reference

12 December 2020

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

1 reference

12 December 2020

Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study

1 reference

12 December 2020

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

1 reference

12 December 2020

Lenalidomide in multiple myeloma

1 reference

12 December 2020

Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma

1 reference

12 December 2020

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

1 reference

12 December 2020

Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications

1 reference

12 December 2020

Antimyeloma activity of heat shock protein-90 inhibition.

1 reference

12 December 2020

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

1 reference

12 December 2020

Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis

1 reference

12 December 2020

VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma

1 reference

12 December 2020

Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: A Hoosier Oncology Group Trial, HEM01-21.

1 reference

12 December 2020

10.1007/S11899-009-0014-5

Identifiers

DOI

1 reference

22 August 2017

1 reference